A Phase 3 interventional study of Intramuscular olanzapine depot in Schizophrenic Disorders and Schizoaffective Disorder, sponsored by Eli Lilly and Company. Completed at 92 sites in 25 countries. Open to participants aged 18 Years to 76 Years. Per ClinicalTrials.gov, last updated 2012-01-11.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 97 studies testing olanzapine in Schizophrenia — 2 open to participants now, 3 under way, 1 of them phase 3. Olanzapine · Schizophrenia.
Among the 97 studies testing olanzapine in Schizophrenia, this one is the 5th largest by enrollment of the 94 interventional ones that give a count, is one of 10 that started in 2004, is one of 25 in phase 3, and was the 12th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →2 of the 97 studies testing olanzapine in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:
Minerva Neurosciences · Sites in United States
Ages 18–55
Centre for Addiction and Mental Health · Sites in Canada
Ages 18+
By country, each count listing its studies:
Olanzapine: first FDA approval 1996 (ZYPREXA), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 76 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
97 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 8 · Phase 3 25 · Phase 4 46
First in 1997; this study’s year is marked. 10 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 931 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 114 across the 94 interventional studies. Of the 86 that completed or were terminated, 25 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 97 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
33 studies in Schizophrenia by Eli Lilly and Company: 2 open now, 2 under way, none of them phase 3. Of 31 finished, 9 (29%) have results posted.
Among the 33 studies in Schizophrenia by Eli Lilly and Company, this one is the 2nd largest by enrollment of the 29 interventional ones that give a count, is one of 7 that started in 2004, is one of 10 in phase 3, and was the 6th registered.
Eli Lilly and Company’s Schizophrenia studies by the year they started, since 2001.
2 of the studies testing olanzapine in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03781115University of ArizonaProposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia | 2027-02-10 |
| NCT04478838Centre for Addiction and Mental Health"Extended" (Alternate Day) Antipsychotic Dosing | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 97 studies testing olanzapine in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 33 in Schizophrenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a long-term, open-label clinical study designed to enable longer-term treatment of patients completing other clinical studies with intramuscular olanzapine depot.
Key objectives of the study are to:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intramuscular (IM) olanzapine depot flexible dosing and flexible interval
Drug: Intramuscular olanzapine depot
45-405 milligram (mg), intramuscular injection, on a 2-, 3-, or 4-week interval.
Also known as: LY170053, Zyprexa Adhera
Number of Participants With Adverse Events (AE)
The list of serious adverse events (SAE) and other non-serious adverse events (AE) are in Adverse Events Section.
Time frame: Randomization to end of study up to 76 months
Number of Participants With Treatment-Emergent Abnormal High Prolactin at Any Time Post Baseline
Prolactin normal reference ranges for female: 2.0 - 29.0 nanograms per milliliter (ng/mL); male: 2.0 - 20.0 ng/mL. High value is defined as a change from a value less than or equal to the high limit at all baseline visits to a value greater than the high limit at any time after baseline.
Time frame: Randomization to end of study up to 76 months
Number of Participants With Treatment-Emergent Abnormal High Alanine Transaminase (ALT), High Aspartate Transaminase (AST), High Total Bilirubin at Any Time Post Baseline
High ALT is defined as a baseline value of \<3 times the upper limit of normal (ULN) to ≥3 times the ULN at any time post baseline. High AST is defined as a baseline value of \<5 times the ULN to ≥5 times the ULN at any time post baseline. High total bilirubin is defined as a baseline value of \<2 times the ULN to ≥2 times the ULN at any time post baseline.
Time frame: Randomization to end of study up to 76 months
Number of Participants Having Normal Fasting Baseline Glucose Value With Treatment-Emergent High Fasting Glucose at Any Time Post Baseline
Normal to high fasting glucose ≤100 milligrams per deciliter (mg/dL) at baseline to ≥126 mg/dL any time post baseline.
Time frame: Randomization to end of study up to 76 months
Number of Participants Having Normal Fasting Baseline Lipid Value With Treatment-Emergent High Fasting Lipid at Any Time Post Baseline
Normal to high fasting total cholesterol ≤200 mg/dL at baseline to ≥240 mg/dL any time post baseline. Fasting triglycerides \<150 mg/dL at baseline to ≥200 mg/dL and \<500 mg/dL any time post baseline.
Time frame: Randomization to end of study up to 76 months
Change From Baseline in Weight at Month 76 Endpoint
Mean change in weight from baseline to last observation carried forward (LOCF) endpoint.
Time frame: Baseline, up to 76 months
Number of Participants With Potentially Clinically Significant (PCS) Weight Gain at Month 76 Endpoint
PCS weight gain is defined as a ≥7% increase in weight from baseline.
Time frame: Randomization to end of study up to 76 months
Number of Participants With Extrapyramidal Symptoms at Any Time
Extrapyramidal symptoms are defined as Simpson-Angus total score (SAS) \>3 at any post-baseline visit; Barnes Akathisia Scale (BAS) global score ≥2 at any post-baseline visit; A score ≥3 for any of Abnormal Involuntary Movement Scale (AIMS) for items 1-7 or a score ≥2 for any two of these items. Score for SAS is 0-4 for each of the 10 questions, with 0=normal and 4=extreme. The possible total score for SAS is 0-40. Possible score for BAS is 0-5, with 0=absent and 5=sever. Score 0-4 for each item of AIMS, with 0 =none and 4= sever. Possible total score for items 1-7 is 0-28.
Time frame: Randomization to end of study up to 76 months
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Scores at Month 76 Endpoint
Assesses the positive symptoms, negative symptoms, and general psychopathology specifically associated with schizophrenia. The scale consists of 30 items. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). The sum of the 30 items is defined as the PANSS total score and ranges from 30 to 210.
Time frame: Baseline, up to 76 months
Change From Baseline in PANSS Positive Scores at Month 76 Endpoint
PANSS questions 1-7. Assesses positive symptoms associated with schizophrenia. 7 items make up the positive scale (ex. delusions, conceptual disorganization, and hallucinatory behavior). Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Total positive subscale scores range from 7 to 49.
Time frame: Baseline, up to 76 months
Change From Baseline in PANSS Negative Scores at Month 76 Endpoint
PANSS questions 8-14. Assesses negative symptoms associated with schizophrenia. 7 items make up the negative scale (e.g. blunted affect, emotional withdrawal, poor rapport, and passive/apathetic social withdrawal). Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Total negative subscale scores range from 7 to 49.
Time frame: Baseline, up to 76 months
Change From Baseline in PANSS General Psychopathology Subscales at Month 76 Endpoint
PANSS General Psychopathology Subscale is the Remaining 16 PANSS questions or PANSS Question15 through Question 30. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). The sum of the 16 items is defined as the PANSS General Psychopathology Subscales. Possible score ranges from 16 to 112.
Time frame: Baseline, up to 76 months
Change From Baseline in Clinical Global Impression-Severity of Illness (CGI-S) Scores at Month 72 Endpoint
Measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).
Time frame: Baseline, up to 72 months
Change From Baseline in the Heinrichs-Carpenter Quality of Life Scale (QLS) Total Score at Month 76 Endpoint
Heinrich-Carpenter QLS is an interviewer-rated scale which measures the impact of negative symptoms on occupational, social, and psychological functioning in patients with schizophrenia or schizoaffective disorder. Each of 21 items is rated on a scale from 0 (severely impaired functioning) to 6 (normal or adequate functioning), for a total score range of 0-126. Results are presented as change in Total score.
Time frame: Baseline, up to 76 months
Change From Baseline in 36-Item Short Form Health Survey (SF-36) at Month 76 Endpoint
A self-reported questionnaire that consists of 36 questions covering 8 health domains (physical functioning, social functioning, bodily pain, vitality, mental health, role-physical, role-emotional and general health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale, with higher scores indicating better health status or functioning. The mental component summary (MCS) and the physical component summary (PCS) have been constructed based on the 8 SF-36 domains.
Time frame: Baseline, up to 76 months
Number of Psychiatric Visits
Psychiatric visits were outpatient visits to a psychiatrist or psychiatric nurse.
Time frame: Randomization to end of study up to 76 months
Days of Hospitalization
This is the total number of days for all hospitalized patients that were admitted to General, Psychiatric Ward as well as Intensive Care Unit (ICU).
Time frame: Randomization to end of study up to 76 months
Change From Baseline in the Subjective Well-Being Under Neuroleptic Treatment-Short Form (SWN-S) at Month 76 Endpoint
The Subjective Well-Being under Neuroleptic Treatment-Short Form (SWN-S) is a patient self-rated scale developed to measure the subjective well-being for the previous 7 days of a patient under neuroleptic treatment. The SWN-S consists of 20 items (each item is rated from 1=not at all to 6=very much). Possible total score ranges from 20-120.
Time frame: Baseline, up to 76 months
Patient Satisfaction With Medication Questionnaire-Modified (PSMQ) at Month 76 Endpoint
Self-rated scale that measures patient's level of satisfaction with current antipsychotic medication. Consists of 3 items assessing satisfaction with current study medication (scored from 1='very dissatisfied' to 5='very satisfied'), preference comparing current study medication versus previous medications (scored from 1='much prefer previous medication' to 5='much prefer study medication'), and side effects of current study medication compared with previous medications (scored from 1='much less side effects' to 5='much more side effects'). Range of possible scores is 3-15.
Time frame: Randomization to end of study up to 76 months
Plasma Olanzapine Concentrations in Participants During Long-Term Treatment by Year
Plasma olanzapine concentrations are expressed as (nanogram/milliliter)/(milligram/day) (\[ng/mL\]/\[mg/day\]).
Time frame: Randomization to end of study up to 76 months
| Milestone | Intramuscular Olanzapine Depot |
|---|---|
| Started | 931 |
| Completed | 370 |
| Not completed | 561 |
| Withdrew: Withdrawal by subject | 290 |
| Withdrew: Adverse event | 77 |
| Withdrew: Lost to follow-up | 57 |
| Withdrew: Physician decision | 45 |
| Withdrew: Sponsor decision | 37 |
| Withdrew: Lack of efficacy | 27 |
| Withdrew: Protocol violation | 17 |
| Withdrew: Death | 11 |
The list of serious adverse events (SAE) and other non-serious adverse events (AE) are in Adverse Events Section.
| participants | Intramuscular Olanzapine Depot |
|---|---|
| AE | 501 |
| SAE | 170 |
Assesses the positive symptoms, negative symptoms, and general psychopathology specifically associated with schizophrenia. The scale consists of 30 items. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). The sum of the 30 items is defined as the PANSS total score and ranges from 30 to 210.
| units on a scale | Intramuscular Olanzapine Depot |
|---|---|
| Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Scores at Month 76 Endpoint | 0.30 ± 16.42 |
PANSS questions 1-7. Assesses positive symptoms associated with schizophrenia. 7 items make up the positive scale (ex. delusions, conceptual disorganization, and hallucinatory behavior). Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Total positive subscale scores range from 7 to 49.
| units on a scale | Intramuscular Olanzapine Depot |
|---|---|
| Change From Baseline in PANSS Positive Scores at Month 76 Endpoint | 0.21 ± 4.69 |
PANSS questions 8-14. Assesses negative symptoms associated with schizophrenia. 7 items make up the negative scale (e.g. blunted affect, emotional withdrawal, poor rapport, and passive/apathetic social withdrawal). Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Total negative subscale scores range from 7 to 49.
| units on a scale | Intramuscular Olanzapine Depot |
|---|---|
| Change From Baseline in PANSS Negative Scores at Month 76 Endpoint | -0.08 ± 5.14 |
PANSS General Psychopathology Subscale is the Remaining 16 PANSS questions or PANSS Question15 through Question 30. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). The sum of the 16 items is defined as the PANSS General Psychopathology Subscales. Possible score ranges from 16 to 112.
| units on a scale | Intramuscular Olanzapine Depot |
|---|---|
| Change From Baseline in PANSS General Psychopathology Subscales at Month 76 Endpoint | 0.19 ± 8.51 |
Measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).
| units on a scale | Intramuscular Olanzapine Depot |
|---|---|
| Change From Baseline in Clinical Global Impression-Severity of Illness (CGI-S) Scores at Month 72 Endpoint | -0.17 ± 0.03 |
Heinrich-Carpenter QLS is an interviewer-rated scale which measures the impact of negative symptoms on occupational, social, and psychological functioning in patients with schizophrenia or schizoaffective disorder. Each of 21 items is rated on a scale from 0 (severely impaired functioning) to 6 (normal or adequate functioning), for a total score range of 0-126. Results are presented as change in Total score.
| units on a scale | Intramuscular Olanzapine Depot |
|---|---|
| Change From Baseline in the Heinrichs-Carpenter Quality of Life Scale (QLS) Total Score at Month 76 Endpoint | 6.75 ± 18.55 |
A self-reported questionnaire that consists of 36 questions covering 8 health domains (physical functioning, social functioning, bodily pain, vitality, mental health, role-physical, role-emotional and general health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale, with higher scores indicating better health status or functioning. The mental component summary (MCS) and the physical component summary (PCS) have been constructed based on the 8 SF-36 domains.
| units on a scale | Intramuscular Olanzapine Depot |
|---|---|
| Mental component summary | 0.94 ± 11.05 |
| Physical component summary | -0.36 ± 8.34 |
Psychiatric visits were outpatient visits to a psychiatrist or psychiatric nurse.
| visits | Intramuscular Olanzapine Depot |
|---|---|
| Number of Psychiatric Visits | 14102 |
This is the total number of days for all hospitalized patients that were admitted to General, Psychiatric Ward as well as Intensive Care Unit (ICU).
| days | Intramuscular Olanzapine Depot |
|---|---|
| Regular hospital | 2386 |
| Psychiatric hospital | 35587 |
| ICU | 134 |
The Subjective Well-Being under Neuroleptic Treatment-Short Form (SWN-S) is a patient self-rated scale developed to measure the subjective well-being for the previous 7 days of a patient under neuroleptic treatment. The SWN-S consists of 20 items (each item is rated from 1=not at all to 6=very much). Possible total score ranges from 20-120.
| units on a scale | Intramuscular Olanzapine Depot |
|---|---|
| Change From Baseline in the Subjective Well-Being Under Neuroleptic Treatment-Short Form (SWN-S) at Month 76 Endpoint | 0.86 ± 15.96 |
Self-rated scale that measures patient's level of satisfaction with current antipsychotic medication. Consists of 3 items assessing satisfaction with current study medication (scored from 1='very dissatisfied' to 5='very satisfied'), preference comparing current study medication versus previous medications (scored from 1='much prefer previous medication' to 5='much prefer study medication'), and side effects of current study medication compared with previous medications (scored from 1='much less side effects' to 5='much more side effects'). Range of possible scores is 3-15.
| percent of participants | Intramuscular Olanzapine Depot |
|---|---|
| Depot, somewhat or very satisfied | 73.2 |
| Depot vs. oral, prefer or much prefer | 66.8 |
| Depot vs. oral, less or much less side effects | 73.3 |
Plasma olanzapine concentrations are expressed as (nanogram/milliliter)/(milligram/day) (\[ng/mL\]/\[mg/day\]).
| (ng/mL)/(mg/day) | Intramuscular Olanzapine Depot |
|---|---|
| 0.25 year (n= 130) | 2.23 ± 1.34 |
| 1 year (n= 189) | 2.51 ± 1.30 |
| 2 years (n= 166) | 2.45 ± 1.32 |
| 3 years (n= 148) | 2.65 ± 1.39 |
| 4 years (n= 109) | 2.57 ± 1.72 |
| 5 years (n= 87) | 2.59 ± 1.46 |
| 6 years (n= 28) | 2.73 ± 1.25 |
Prolactin normal reference ranges for female: 2.0 - 29.0 nanograms per milliliter (ng/mL); male: 2.0 - 20.0 ng/mL. High value is defined as a change from a value less than or equal to the high limit at all baseline visits to a value greater than the high limit at any time after baseline.
| participants | Intramuscular Olanzapine Depot |
|---|---|
| Number of Participants With Treatment-Emergent Abnormal High Prolactin at Any Time Post Baseline | 100 |
High ALT is defined as a baseline value of \<3 times the upper limit of normal (ULN) to ≥3 times the ULN at any time post baseline. High AST is defined as a baseline value of \<5 times the ULN to ≥5 times the ULN at any time post baseline. High total bilirubin is defined as a baseline value of \<2 times the ULN to ≥2 times the ULN at any time post baseline.
| participants | Intramuscular Olanzapine Depot |
|---|---|
| ALT (n=901) | 61 |
| AST (n=909) | 55 |
| Total Bilirubin (n=912) | 24 |
Normal to high fasting glucose ≤100 milligrams per deciliter (mg/dL) at baseline to ≥126 mg/dL any time post baseline.
| participants | Intramuscular Olanzapine Depot |
|---|---|
| Number of Participants Having Normal Fasting Baseline Glucose Value With Treatment-Emergent High Fasting Glucose at Any Time Post Baseline | 20 |
Normal to high fasting total cholesterol ≤200 mg/dL at baseline to ≥240 mg/dL any time post baseline. Fasting triglycerides \<150 mg/dL at baseline to ≥200 mg/dL and \<500 mg/dL any time post baseline.
| participants | Intramuscular Olanzapine Depot |
|---|---|
| Cholesterol (n=873) | 28 |
| Triglycerides (n=879) | 41 |
Mean change in weight from baseline to last observation carried forward (LOCF) endpoint.
| kilogram (kg) | Intramuscular Olanzapine Depot |
|---|---|
| Change From Baseline in Weight at Month 76 Endpoint | 2.10 ± 7.81 |
PCS weight gain is defined as a ≥7% increase in weight from baseline.
| participants | Intramuscular Olanzapine Depot |
|---|---|
| Number of Participants With Potentially Clinically Significant (PCS) Weight Gain at Month 76 Endpoint | 373 |
Extrapyramidal symptoms are defined as Simpson-Angus total score (SAS) \>3 at any post-baseline visit; Barnes Akathisia Scale (BAS) global score ≥2 at any post-baseline visit; A score ≥3 for any of Abnormal Involuntary Movement Scale (AIMS) for items 1-7 or a score ≥2 for any two of these items. Score for SAS is 0-4 for each of the 10 questions, with 0=normal and 4=extreme. The possible total score for SAS is 0-40. Possible score for BAS is 0-5, with 0=absent and 5=sever. Score 0-4 for each item of AIMS, with 0 =none and 4= sever. Possible total score for items 1-7 is 0-28.
| participants | Intramuscular Olanzapine Depot |
|---|---|
| SAS (n=819) | 66 |
| BAS (n=856) | 34 |
| AIMS (n=860) | 28 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Intramuscular Olanzapine Depot | — | 170/931 (18.3%) | 501/931 (53.8%) |
| Event | Intramuscular Olanzapine Depot |
|---|---|
| SchizophreniaPsychiatric disorders | 35/931 |
| Psychotic disorderPsychiatric disorders | 20/931 |
| SedationNervous system disorders | 12/931 |
| Suicidal ideationPsychiatric disorders | 8/931 |
| AgitationPsychiatric disorders | 6/931 |
| SomnolenceNervous system disorders | 5/931 |
| AnxietyPsychiatric disorders | 5/931 |
| DepressionPsychiatric disorders | 5/931 |
| ParanoiaPsychiatric disorders | 5/931 |
| AggressionPsychiatric disorders | 4/931 |
| Event | Intramuscular Olanzapine Depot |
|---|---|
| Weight increasedInvestigations | 134/931 |
| AnxietyPsychiatric disorders | 90/931 |
| InsomniaPsychiatric disorders | 90/931 |
| SomnolenceNervous system disorders | 85/931 |
| NasopharyngitisInfections and infestations | 74/931 |
| HeadacheNervous system disorders | 67/931 |
| DizzinessNervous system disorders | 50/931 |
| DepressionPsychiatric disorders | 48/931 |
| Age Continuous(years) | Intramuscular Olanzapine Depot |
|---|---|
| Mean | 39.32 ± 11.67 |
| Sex: Female, Male(Participants) | Intramuscular Olanzapine Depot |
|---|---|
| Female | 310 |
| Male | 621 |
| Race/Ethnicity, Customized(participants) | Intramuscular Olanzapine Depot |
|---|---|
| African | 102 |
| Caucasian | 629 |
| East Asian | 39 |
| Hispanic | 140 |
| Native American | 2 |
| West Asian | 19 |
| Region of Enrollment(participants) | Intramuscular Olanzapine Depot |
|---|---|
| United States | 177 |
| Portugal | 18 |
| Taiwan | 30 |
| Slovakia | 13 |
| Spain | 24 |
| Russian Federation | 114 |
| Israel | 29 |
| Italy | 6 |
| France | 55 |
| Puerto Rico | 27 |
| Australia | 11 |
| South Africa | 28 |
| Netherlands | 8 |
| Austria | 10 |
| Czech Republic | 3 |
| Hungary | 13 |
| Mexico | 63 |
| Argentina | 73 |
| Poland | 33 |
| Brazil | 89 |
| Belgium | 13 |
| Croatia | 16 |
| Romania | 34 |
| Germany | 32 |
| Sweden | 9 |
| Greece | 3 |
The record gives a start of Aug 2004, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2012, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olanzapine